Jeffrey Cummings, AAN 2019 – Emerging Alzheimer therapies and considerations for future research
US Neurology Editorial Board member, Jeffrey Cummings (UNVL Department of Brain Health and Cleveland Clinic Lou Ruvo Center for Brain Health, California, USA), considers both successes and failures with emerging new treatments for Alzheimer’s disease, and important steps to be taken to improve future clinical trial design.
1. What is the current status of the clinical development of monoclonal antibodies (mAbs) against the amyloid-β peptide? (0:04)
2. What is the rationale for repurposing drugs such as rasagiline in Alzheimer’s disease (AD)? (1:20)
3. What makes rasagiline particularly attractive as a potential AD treatment? (1:55)
4. What are the current unmet needs in AD research? (2:31)
5. Given the clinical trial failures in AD, how can we improve clinical trial design in the future? (3:23)
Speaker disclosures: Dr Cummings has provided consultation to Acadia, Accera, Actinogen, AgeneBio, Alkahest, Allergan, Alzheon, Avanir, Axsome, Binomics, BiOasis Technologies, Biogen, Bracket, Denali, Diadem, EIP Pharma, Eisai, Genentech, Green Valley, Grifols, Hisun, Idorsia, Lundbeck, MedAvante, Merck, Otsuka, Pain Therapeutics, Probiodrug, Proclara, QR, Resverlogix, Roche, Samumed, Shinkei Therapeutics, Sunovion, Suven, Takeda, and United Neuroscience pharmaceutical and assessment companies. He has also provided consultation to Global Alzheimer Platform (GAP). Dr Cummings owns the copyright of the Neuropsychiatric Inventory (NPl) and is the Chief Scientific Officer of CNS Innovations. He owns stock in ADAMAS, BioAsis, MedAvante, and QR Pharma. He receives the following NIH support: COBRE grant # P20GMI09025; TRC-PAD # R01AG053798; DIAGNOSE CTE # UOINS093334.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Kristen George, AAIC 2022: Experiences of discrimination on cognitive function and ageing among the oldest old: The LifeAfter90 (LA90) Study
The LifeAfter90 (LA90) Study aims to understand what cognitive ageing and dementia look like among individuals aged 90 and above. In this interview, Dr Kristen George (University of California Davis School of Medicine, University of California, Davis, CA, USA) discussed what the study found in terms of the effect of discrimination on the cognitive function of this […]
Claire Sexton: Highlights of AAIC 2022
The Alzheimer’s Association International Conference (AAIC) is the largest and most influential meeting dedicated to advancing Alzheimer’s and dementia research. Each year, it gathers researchers to share discoveries that’ll lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer’s disease. Dr Claire Sexton is the senior director of Scientific Programs […]
Dr Jennifer Bute: Living with dementia – the importance of laughter and hope
Dr Jennifer Bute is a retired GP living with dementia. She shares her experiences of diagnosis and describes the strategies that are helpful for her. Jennifer also highlights the importance of laughter, engagement and hope. Touch Medical Media is sharing educational resources on World Brain Day (22 July 2022) to help achieve brain health for […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!